Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b study evaluating the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory follicular lymphoma (FL)

Next Previous
X
Search
Trial Profile

A Phase 1b study evaluating the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory follicular lymphoma (FL)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Plamotamab (Primary) ; Tafasitamab (Primary)
  • Indications Follicular lymphoma
  • Focus Adverse reactions
  • Sponsors Xencor

    • Most Recent Events

    • 09 Jan 2023 According to Xencor media release, the company intends to continue the enrollment of patients in this study.
    • 05 May 2022 According to a Xencor media release, the Company plans to present data from the expansion cohorts in the second half of 2022.
    • 24 Nov 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top